Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
SAN FRANCISCO, Nov. 9, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host a webcast analyst and investor conference call with a cancer specialist and Nektar mana
Nektar (NKTR) Q3 Earnings Top, Pipeline Remains On Track
12:13pm, Friday, 05'th Nov 2021
Nektar (NKTR) reports mixed third-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.
Nektar Therapeutics (NKTR) CEO Howard Robin on Q3 2021 Results - Earnings Call Transcript
11:47pm, Thursday, 04'th Nov 2021
Nektar Therapeutics (NKTR) CEO Howard Robin on Q3 2021 Results - Earnings Call Transcript
Nektar Therapeutics (NKTR) Reports Q3 Loss, Misses Revenue Estimates
07:04pm, Thursday, 04'th Nov 2021
Nektar (NKTR) delivered earnings and revenue surprises of 12.50% and -16.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
SAN FRANCISCO, Oct. 26, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2021 on Thursday, November 4, 2021, after the close of U.S
Nektar Therapeutics' Short Covering Surges By 200% In 2 Weeks
12:30pm, Wednesday, 29'th Sep 2021
Short covering has accelerated dramatically as the price bottomed and recovered.
Nektar Sends Shot Across Bristol Myers Squibb's Bow With Big Pfizer Collaboration
08:11am, Thursday, 23'rd Sep 2021
The collaboration is a clear message sent from Nektar CEO Howard Robin that any acquisition has to fairly value Nektar's ENTIRE portfolio. Pfizer may have bigger plans in store for Nektar.
Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255
12:16pm, Wednesday, 22'nd Sep 2021
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
11:02am, Tuesday, 21'st Sep 2021
Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE: PFE) to evaluate the maintenance regimen of NKTR
SAN FRANCISCO, Sept. 21, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced it has entered into a new oncology clinical collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc.
Nektar And Bristol Myers Squibb Expecting Bempeg Approval
08:00am, Saturday, 18'th Sep 2021
All signs point to approval of Bempeg, Nektar's flagship anti-cancer compound. Retail investors are still caught in the web of lies propagated by Short & Distort operators.
Nektar Therapeutics Stock Performance In The Pandemic vs 2008
08:30am, Thursday, 09'th Sep 2021
We believe that Nektar Therapeutics stock, a biopharmaceutical company focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic pain, is a good buy
Mr. Manipulation Meets Ms. Opportunity At The Nektar Cocktail Party
10:37am, Friday, 27'th Aug 2021
Mr. Manipulation Meets Ms. Opportunity At The Nektar Cocktail Party
SAN FRANCISCO, July 27, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2021 on Thursday, August 5, 2021, after the close of U.S.
Nektar Appoints Dimitry S.A. Nuyten, M.D.
09:00am, Monday, 19'th Jul 2021
SAN FRANCISCO, July 19, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has appointed Dimitry S.A. Nuyten, M.D.
